Transcenta Holding Limited 6628
HKEX · Hong Kong SAR China · Health Technology
HKD 0.9000-0.09 (-9.55%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Transcenta Therapeutics (HKEX: 06628), a global clinical-stage biopharmaceutical company with fully integrated capabilities in discovery, R&D and process development of antibody-based therapeutics, today announced that it and its subsidiary, HJB, have entered into a technology licensing and strategic collaboration agreement with WuXi Biologics. Under the agreement, Transcenta will grant WuXi Biologics and its affiliates a non-exclusive license to certain technologies relating to Transcenta's Hig
PRINCETON, N.J. and SUZHOU, China, April 23, 2026 (GLOBE NEWSWIRE) -- Transcenta Therapeutics (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced the presentation of preclinical data highlighting its proprietary LIV1-targeting antibody-drug conjugates (ADC) at the 2026 AACR Annual Meeting. The data demonstrate strong anti-tumor activity, differenti
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.